A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies

Eli Lilly Japan K.K.0 个研究点开始时间: 2012年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Part A Have histological or cytological evidence of malignancies (solid tumor or lymphoma) that are advanced and/or metastatic. The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have been used.
•Part B1 Have histological or cytological diagnosis of advanced NSCLC, stage IV. Patients must be eligible for erlotinib therapy.
•Part B2 Have histological or cytological diagnosis of advanced NSCLC, stage IV. Patients must be eligible for gefinitib therapy.
•- Have adequate hematologic, hepatic and renal function.
•- Have a performance status of equal to or less than 2.
•- Have discontinued all previous cancer therapies, and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half lives prior to study enrollment, whichever is shorter, and recovered from the acute effects of therapy
•- Have an estimated life expectancy, that will permit the participant to complete 8 weeks of treatment.

发起方